← Back to guidelines
Cardiology3 papers

Acute mitral regurgitation from chordal rupture

Last edited: 4/10/2026

Overview

Acute mitral regurgitation (MR) can result from chordal rupture, leading to significant hemodynamic compromise. Transcatheter edge-to-edge repair (TEER) is a minimally invasive option for patients with prohibitive surgical risks 1.

Diagnosis

  • Diagnosis is typically made via echocardiography, which can identify the severity of MR and the underlying cause, such as chordal rupture.
  • Management

  • Transcatheter edge-to-edge repair (TEER) is an option for patients with prohibitive surgical risks 1.
  • Devices for TEER include the MitraClip and the PASCAL system 1.
  • Technical success rates for TEER are high, with MR ≤2 at 30-day follow-up reported in approximately 89-90% of patients 1.
  • Outcomes, including all-cause mortality, major bleeding, and reintervention rates, are comparable between the MitraClip and PASCAL devices 1.
  • Device success was more frequent with the PASCAL device, though not statistically significant in one meta-analysis 1.
  • Key Recommendations

  • Transcatheter edge-to-edge repair (TEER) is a feasible treatment option for mitral regurgitation in patients with prohibitive surgical risks 1. (Evidence: Moderate)
  • Both the MitraClip and PASCAL devices demonstrate comparable safety and effectiveness for TEER, with similar rates of technical success and MR reduction at 30 days 1. (Evidence: Moderate)
  • The choice between MitraClip and PASCAL devices should be guided by specific factors, though these are not detailed in the provided abstract 1. (Evidence: Expert opinion)
  • References

    1 Alqeeq BF, Al-Tawil M, Hamam M, Aboabdo M, Elrayes MI, Leick J et al.. Transcatheter edge-to-edge repair in mitral regurgitation: A comparison of device systems and recommendations for tailored device selection. A systematic review and meta-analysis. Progress in cardiovascular diseases 2023. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG